Skip to Content
Merck
  • A platform for artificial intelligence based identification of the extravasation potential of cancer cells into the brain metastatic niche.

A platform for artificial intelligence based identification of the extravasation potential of cancer cells into the brain metastatic niche.

Lab on a chip (2019-02-28)
C Ryan Oliver, Megan A Altemus, Trisha M Westerhof, Hannah Cheriyan, Xu Cheng, Michelle Dziubinski, Zhifen Wu, Joel Yates, Aki Morikawa, Jason Heth, Maria G Castro, Brendan M Leung, Shuichi Takayama, Sofia D Merajver
ABSTRACT

Brain metastases are the most lethal complication of advanced cancer; therefore, it is critical to identify when a tumor has the potential to metastasize to the brain. There are currently no interventions that shed light on the potential of primary tumors to metastasize to the brain. We constructed and tested a platform to quantitatively profile the dynamic phenotypes of cancer cells from aggressive triple negative breast cancer cell lines and patient derived xenografts (PDXs), generated from a primary tumor and brain metastases from tumors of diverse organs of origin. Combining an advanced live cell imaging algorithm and artificial intelligence, we profile cancer cell extravasation within a microfluidic blood-brain niche (μBBN) chip, to detect the minute differences between cells with brain metastatic potential and those without with a PPV of 0.91 in the context of this study. The results show remarkably sharp and reproducible distinction between cells that do and those which do not metastasize inside of the device.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Blood-Brain Barrier hCMEC/D3 Cell Line, The hCMEC/D3 BBB cell line has been extensively characterized for brain endothelial phenotype and is a model of human blood-brain barrier (BBB) function.